Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Dysrhythmias I: Introduction

Dysrhythmias I: Introduction

Dysrhythmias refers to abnormalities in the heart's rhythm. They result from disruptions in the heart's electrical conduction system, which includes the sinoatrial(SA)node, atrioventricular(AV) node, the bundle of His, bundle branches, and Purkinje fibers.Definition and PathophysiologyDysrhythmias result from disorders of impulse formation, impulse conduction, or both. The heart contains specialized cells in the sinoatrial node, atrioventricular node, and the bundle of His and Purkinje fibers...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Dysrhythmias VII: Nursing Management of Dysrhythmias

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Theoretical and Scientific Underpinnings of Peripheral Muscle Electrostimulation in Cardiac Rehabilitation of the Elderly: A Systematic Review.

Journal of clinical medicine·2026

Same author

Low-latency HRV analysis from ultra-short ECG windows using a modular deep-learning framework.

Scientific reports·2026

Same author

A novel method of diagnosing and monitoring cardiac arrhythmias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Polish archives of internal medicine·2025

Same author

Guidelines for the management of hypertension in Poland 2024 - the position paper of the Polish Society of Hypertension and Polish Cardiac Society experts.

Kardiologia polska·2025

Same author

Association of pre-existing comorbidities and complications with inpatient COVID-19 mortality - a single-center retrospective study.

Cardiology journal·2025

Same author

Corrigendum to "Effectiveness of antazoline versus amiodarone, flecainide and propafenone in restoring sinus rhythm at the emergency department" [Adv. Med. Sci (2024 Sep) 69(2) 248-255].

Advances in medical sciences·2025

Search research articles

Related Experiment Video

Updated: May 31, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dronedarone: an overview.

Dariusz Kozlowski¹, Szymon Budrejko, Gregory Y H Lip

¹Department of Cardiology and Electrotherapy, Second Chair of Cardiology, Medical University of Gdansk, Poland.

Annals of Medicine

|July 13, 2011

Summary

Dronedarone offers a safer alternative for atrial fibrillation (AF) rhythm control compared to amiodarone, with reduced organ toxicity. However, its antiarrhythmic efficacy may be less potent than amiodarone.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Experiment Videos

Last Updated: May 31, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Area of Science:

Cardiology
Pharmacology

Background:

Atrial fibrillation (AF) is a prevalent clinical arrhythmia.
Rhythm control strategies for AF were historically limited by drug toxicity.
Newer antiarrhythmic agents aim to improve safety and efficacy.

Purpose of the Study:

To evaluate dronedarone as a novel antiarrhythmic drug for atrial fibrillation.
To compare the safety and efficacy profile of dronedarone with amiodarone.

Main Methods:

Review of clinical trials investigating dronedarone in AF.
Indirect and direct comparisons of dronedarone versus amiodarone.

Main Results:

Dronedarone demonstrates efficacy in preventing AF recurrence and controlling heart rate.
Dronedarone is associated with reduced organ toxicity compared to amiodarone.
Studies suggest dronedarone may have lower antiarrhythmic efficacy than amiodarone.

Conclusions:

Dronedarone presents a promising, safer option for AF rhythm control.
The improved safety profile of dronedarone might be associated with a trade-off in antiarrhythmic potency.